Next-Generation Allergen-Specific Immunotherapy for Japanese Cedar Pollinosis Using Molecular Approaches

Area of Science:

• Immunology
• Allergy Research
• Biotechnology

Background:

• Japanese cedar (JC) pollinosis is a prevalent allergic disease in Japan, primarily mediated by IgE.
• Current immunotherapies (subcutaneous and sublingual) for JC pollinosis have limitations, including adverse side effects due to allergen cross-linking with IgE on mast cells and basophils.

Purpose of the Study:

• To develop safer, more effective, and convenient immunotherapy options for JC pollinosis.
• To evaluate the efficacy and safety of novel rice-based oral allergy vaccines and other advanced vaccine strategies.

Main Methods:

• Development of rice-based oral allergy vaccines using hybrid peptides from JC allergens (Cry j 1, Cry j 2) or their recombinant hypoallergenic derivatives.
• Oral administration of transgenic rice seeds containing these engineered allergens.
• Creation and assessment of recombinant modified JC allergens conjugated with immunomodulatory molecules and DNA-based vaccines.

Main Results:

• Transgenic rice seeds expressing hybrid peptides or hypoallergenic JC allergen derivatives were developed.
• Efficacy and safety of these novel vaccine candidates were evaluated through oral administration.
• Preliminary assessments of modified JC allergens and DNA-based vaccines were conducted.

Conclusions:

• Rice-based oral allergy vaccines represent a promising advancement for JC pollinosis treatment, potentially overcoming the limitations of current immunotherapies.
• Further research into modified allergens and DNA vaccines may offer additional therapeutic avenues for Japanese cedar allergy.